1. Clinical diagnosis and justification (type, activity, complications, comorbidities)
2. Interpretation of the given laboratory and instrumental data
3. Additional investigations to order, and the characteristic disease changes
4. Non-pharmacological management
5. Pharmacological therapy (etiological, pathogenetic, symptomatic, replacement)
6. Annual follow-up and routine monitoring plan

• Two years of symptoms (thirst, polyuria, dry mouth).
• Obesity (body mass index 33) and a sedentary, high-carbohydrate lifestyle.
• Fasting glucose 9.6 mmol/L and postprandial glucose 13 mmol/L, despite metformin.
• Glycated hemoglobin is not given, so activity (degree of compensation) must be confirmed with it.
• Chronic pancreatitis is a trap. It raises the possibility of secondary (pancreatogenic, type 3c) diabetes, which I would address in the differential diagnosis.

• Diabetic retinopathy, non-proliferative, with macular edema in both eyes.
• Diabetic kidney disease (chronic kidney disease, eGFR about 73, stage G2). Proteinuria of 0.33 g/L suggests at least moderately increased albuminuria. The albumin-to-creatinine ratio is needed to stage it.
• Probable diabetic polyneuropathy. This needs confirming on examination.
• Possible chronic pyelonephritis or urinary tract infection. Leukocyturia, a weakly positive tapping sign, and a dilated pelvis and calyces on ultrasound point this way.

• Class I obesity.
• Arterial hypertension, grade 2 to 3 (160/100 mm Hg), with probable hypertensive heart disease.
• Mixed dyslipidemia (total cholesterol 6.9, triglycerides 2.7, HDL cholesterol 1.0 mmol/L).
• Chronic pancreatitis and chronic cholecystitis.

• Urine specific gravity of 1035 with only trace glucose reflects concentrated, proteinuric urine.
• Normal blood count and ESR argue against active systemic inflammation.
• Enlarged kidneys with a thickened cortex may fit early diabetic nephropathy (hyperfiltration and hypertrophy). A heterogeneous parenchyma and dilated collecting system raise the possibility of obstruction or infection.

• Lifestyle: calorie-restricted, low-glycemic diet, graded physical activity, weight loss, and sleep and shift-work hygiene.
• Glucose lowering: continue and titrate metformin, which is acceptable at an eGFR of about 73. Add a sodium-glucose cotransporter 2 inhibitor for cardiorenal protection. Use glucagon-like peptide-1 agonists and dipeptidyl peptidase-4 inhibitors with caution, or avoid them, because of chronic pancreatitis. Insulin is likely if the diabetes is pancreatogenic or glycemic control stays poor.
• Blood pressure and kidney protection: an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, plus a calcium channel blocker or thiazide-like diuretic as needed, and consider finerenone.
• Lipids: a high-intensity statin, with ezetimibe if needed.
• Eyes: ophthalmology referral for anti-vascular endothelial growth factor injections or laser treatment.
• Other: antiplatelet therapy by risk assessment, and treatment of any urinary infection.

Case CC/7: 54-year-old man with type 2 diabetes mellitus

1. Clinical diagnosis and justification

• Bilateral non-proliferative diabetic retinopathy with diabetic macular edema. This is the cause of the progressive vision loss.
• Diabetic kidney disease (diabetic nephropathy), chronic kidney disease with estimated glomerular filtration rate category G2 (60 to 89) and proteinuria. The albuminuria category is provisionally A2 to A3, pending quantification. The diagnosis is provisional until urinary infection is excluded.
• Diabetic peripheral neuropathy is not documented. It must be actively examined for, not assumed absent.

• Arterial hypertension, grade 2 (160/100 mm Hg), with target organ damage (kidney, retina) and probable hypertensive heart disease. Very high cardiovascular risk.
• Obesity, class I (body mass index 33 kg/m²), with metabolic syndrome.
• Mixed atherogenic dyslipidemia.
• Chronic pancreatitis and chronic cholecystitis, both in remission.
• Suspected urinary tract infection or chronic pyelonephritis, to be confirmed.

• Type 2 diabetes mellitus
  • Classic symptoms: dry mouth, thirst, polyuria.
  • Fasting glucose is 9.6 mmol/L (diagnostic at 7.0 or above). Postprandial glucose is 13 mmol/L (11.1 or above).
  • He has obesity, a high-carbohydrate diet, physical inactivity, dyslipidemia and hypertension, and he is already on metformin.
  • Acetone is negative and there is no weight loss.
  • Pancreatogenic diabetes (type 3c) must be considered because of the chronic pancreatitis. It is less likely here given the obesity and insulin-resistance phenotype. C-peptide and fecal elastase can help separate the two.
• Uncompensated: glucose values are well above targets (fasting 4.4 to 7.2, postprandial below 10 mmol/L) and there are already microvascular complications.
• Retinopathy and macular edema: from the ophthalmologist's conclusion.
• Diabetic kidney disease: proteinuria, enlarged kidneys with thick cortex (typical early hyperfiltration pattern), reduced estimated glomerular filtration rate, coexisting retinopathy and hypertension.
• Suspected infection: leukocyturia of 20 to 22 per field, cloudy urine, weakly positive costovertebral angle tapping sign on both sides, and a dilated pelvicalyceal system.
• Hypertension: a muffled first sound and accent of the second sound over the aorta suggest left ventricular hypertrophy and a hypertensive heart. Shortness of breath needs echocardiography.

2. Interpretation of results

• Glycemic:
  • Glycated hemoglobin (essential and missing).
  • C-peptide and insulin.
  • GAD antibodies if the phenotype is atypical.
• Kidney:
  • Urine albumin-to-creatinine ratio, repeated twice within 3 to 6 months, and 24-hour protein.
  • Urine culture and Nechiporenko test.
  • Serum potassium, sodium, uric acid, and cystatin C if needed.
  • Bladder ultrasound with post-void residual volume.
  • Doppler of renal arteries.
• Lipid and liver:
  • Full lipid panel (LDL directly).
  • Alanine and aspartate aminotransferases, gamma-glutamyl transferase, alkaline phosphatase, bilirubin.
  • Liver ultrasound or fibrosis scoring for fatty liver.
• Pancreas:
  • Amylase and lipase.
  • Fecal elastase for exocrine insufficiency.
• Cardiovascular:
  • Electrocardiogram.
  • Echocardiography.
  • Natriuretic peptide if dyspnea persists.
  • 24-hour ambulatory blood pressure monitoring.
  • Carotid duplex and ankle-brachial index.
  • Stress testing if indicated.
• Neuropathy: 10 g monofilament, 128 Hz vibration, pinprick and ankle reflex testing, and orthostatic blood pressure for autonomic neuropathy.
• Other: thyroid-stimulating hormone, vitamin B12, and sleep apnea screening (obesity, night shifts, hypertension).
• Ophthalmology: optical coherence tomography and fluorescein angiography.

3. Management

Non-pharmacological

• Diet:
  • Medical nutrition therapy with a Mediterranean-type pattern and a deficit of 500 to 750 kcal/day.
  • Remove refined carbohydrates and fried food, and reduce saturated fat.
  • Salt below 5 g/day.
  • Protein about 0.8 g/kg/day for kidney disease.
  • Regular meal timing, which matters on night shifts.
  • Complete alcohol avoidance (pancreatitis, hypertriglyceridemia).
• Weight: loss of 5 to 10% or more.
• Activity: 150 minutes/week of moderate aerobic exercise plus resistance training 2 to 3 times/week. Avoid heavy straining and Valsalva-type effort until the macular edema is treated.
• Other lifestyle: stop smoking if applicable, sleep hygiene, and treat sleep apnea if present.
• Education: diabetes school, home glucose and blood pressure monitoring, foot care, hypoglycemia recognition, and sick-day rules.

Pharmacological

• Metformin (biguanide): titrate to 1000 mg twice daily with meals. This is safe at an estimated glomerular filtration rate above 45. Stop it during acute illness or contrast studies if renal function is unstable.
• Sodium-glucose cotransporter 2 inhibitor (empagliflozin 10 mg or dapagliflozin 10 mg daily):
  • Gives kidney, heart and weight benefit.
  • Start only after the urinary infection is treated and obstruction is excluded.
• Avoid:
  • Glucagon-like peptide 1 agonists and dipeptidyl peptidase 4 inhibitors, because of chronic pancreatitis. Semaglutide may also transiently worsen retinopathy if glucose falls too fast.
  • Pioglitazone, because it worsens fluid retention and macular edema.
• Step-up:
  • If the target is not reached in about 3 months, or in a catabolic state, add basal insulin (insulin glargine or degludec, starting at 0.1 to 0.2 units/kg).
  • Gliclazide modified-release is an alternative, but it carries hypoglycemia risk.
  • Lower glucose gradually, because rapid correction can transiently worsen retinopathy.

• Angiotensin-converting enzyme inhibitor (perindopril 5 to 10 mg, ramipril 5 to 10 mg) or angiotensin receptor blocker (losartan 50 to 100 mg, telmisartan 40 to 80 mg), titrated to the maximum tolerated dose. Never combine the two.
• Add amlodipine 5 to 10 mg or indapamide 1.5 mg early, because blood pressure is more than 20/10 mm Hg above target.
• Check creatinine and potassium 1 to 2 weeks after starting or changing the dose. A creatinine rise of up to 30% is acceptable.
• If albuminuria persists with potassium of 5.0 or below, add finerenone (nonsteroidal mineralocorticoid antagonist) 10 to 20 mg.

• High-intensity statin: atorvastatin 40 to 80 mg or rosuvastatin 20 mg (adjust for kidney function). Target LDL below 1.4 mmol/L and at least 50% reduction.
• Add ezetimibe 10 mg if the target is not reached.
• Fenofibrate can be considered for persistent hypertriglyceridemia and may slow retinopathy. Monitor creatinine.
• Antiplatelet therapy (aspirin 75 to 100 mg) for primary prevention is individualized according to bleeding risk.

• Ophthalmologist:
  • Intravitreal anti-vascular endothelial growth factor injections (aflibercept, ranibizumab, faricimab) for center-involving macular edema.
  • Focal or grid laser photocoagulation, or intravitreal corticosteroid implants, if needed.
  • Panretinal photocoagulation if the retinopathy becomes proliferative.
• Urinary infection:
  • Antibiotic chosen by urine culture and sensitivity (for example a cephalosporin or fluoroquinolone).
  • Urologic evaluation of the dilated collecting system.
• Neuropathy, if confirmed: alpha-lipoic acid, and pregabalin, gabapentin or duloxetine for pain.

• Basal or basal-bolus insulin if beta-cell failure or a pancreatogenic component is confirmed.
• Pancreatic enzyme replacement (pancrelipase) if exocrine insufficiency is present.
• Ursodeoxycholic acid or surgical review for chronic cholecystitis or gallstones.
• Review for bariatric surgery if the body mass index remains 30 or more with poor control.
• Vaccination: influenza, pneumococcal, hepatitis B and COVID-19.

Annual follow-up and monitoring

1. Clinical diagnosis and justification (type, activity, complications, comorbidities)
2. Interpretation of the given laboratory and instrumental data
3. Additional investigations to order, and the characteristic disease changes
4. Non-pharmacological management
5. Pharmacological therapy (etiological, pathogenetic, symptomatic, replacement)
6. Annual follow-up and routine monitoring plan

• Two years of symptoms (thirst, polyuria, dry mouth).
• Obesity (body mass index 33) and a sedentary, high-carbohydrate lifestyle.
• Fasting glucose 9.6 mmol/L and postprandial glucose 13 mmol/L, despite metformin.
• Glycated hemoglobin is not given, so activity (degree of compensation) must be confirmed with it.
• Chronic pancreatitis is a trap. It raises the possibility of secondary (pancreatogenic, type 3c) diabetes, which I would address in the differential diagnosis.

• Diabetic retinopathy, non-proliferative, with macular edema in both eyes.
• Diabetic kidney disease (chronic kidney disease, eGFR about 73, stage G2). Proteinuria of 0.33 g/L suggests at least moderately increased albuminuria. The albumin-to-creatinine ratio is needed to stage it.
• Probable diabetic polyneuropathy. This needs confirming on examination.
• Possible chronic pyelonephritis or urinary tract infection. Leukocyturia, a weakly positive tapping sign, and a dilated pelvis and calyces on ultrasound point this way.

• Class I obesity.
• Arterial hypertension, grade 2 to 3 (160/100 mm Hg), with probable hypertensive heart disease.
• Mixed dyslipidemia (total cholesterol 6.9, triglycerides 2.7, HDL cholesterol 1.0 mmol/L).
• Chronic pancreatitis and chronic cholecystitis.

• Urine specific gravity of 1035 with only trace glucose reflects concentrated, proteinuric urine.
• Normal blood count and ESR argue against active systemic inflammation.
• Enlarged kidneys with a thickened cortex may fit early diabetic nephropathy (hyperfiltration and hypertrophy). A heterogeneous parenchyma and dilated collecting system raise the possibility of obstruction or infection.

• Lifestyle: calorie-restricted, low-glycemic diet, graded physical activity, weight loss, and sleep and shift-work hygiene.
• Glucose lowering: continue and titrate metformin, which is acceptable at an eGFR of about 73. Add a sodium-glucose cotransporter 2 inhibitor for cardiorenal protection. Use glucagon-like peptide-1 agonists and dipeptidyl peptidase-4 inhibitors with caution, or avoid them, because of chronic pancreatitis. Insulin is likely if the diabetes is pancreatogenic or glycemic control stays poor.
• Blood pressure and kidney protection: an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, plus a calcium channel blocker or thiazide-like diuretic as needed, and consider finerenone.
• Lipids: a high-intensity statin, with ezetimibe if needed.
• Eyes: ophthalmology referral for anti-vascular endothelial growth factor injections or laser treatment.
• Other: antiplatelet therapy by risk assessment, and treatment of any urinary infection.# Case CC/7: 54-year-old man with type 2 diabetes mellitus

1. Clinical diagnosis and justification

• Bilateral non-proliferative diabetic retinopathy with diabetic macular edema. This is the cause of the progressive vision loss.
• Diabetic kidney disease (diabetic nephropathy), chronic kidney disease with estimated glomerular filtration rate category G2 (60 to 89) and proteinuria. The albuminuria category is provisionally A2 to A3, pending quantification. The diagnosis is provisional until urinary infection is excluded.
• Diabetic peripheral neuropathy is not documented. It must be actively examined for, not assumed absent.

• Arterial hypertension, grade 2 (160/100 mm Hg), with target organ damage (kidney, retina) and probable hypertensive heart disease. Very high cardiovascular risk.
• Obesity, class I (body mass index 33 kg/m²), with metabolic syndrome.
• Mixed atherogenic dyslipidemia.
• Chronic pancreatitis and chronic cholecystitis, both in remission.
• Suspected urinary tract infection or chronic pyelonephritis, to be confirmed.

• Type 2 diabetes mellitus
  • Classic symptoms: dry mouth, thirst, polyuria.
  • Fasting glucose is 9.6 mmol/L (diagnostic at 7.0 or above). Postprandial glucose is 13 mmol/L (11.1 or above).
  • He has obesity, a high-carbohydrate diet, physical inactivity, dyslipidemia and hypertension, and he is already on metformin.
  • Acetone is negative and there is no weight loss.
  • Pancreatogenic diabetes (type 3c) must be considered because of the chronic pancreatitis. It is less likely here given the obesity and insulin-resistance phenotype. C-peptide and fecal elastase can help separate the two.
• Uncompensated: glucose values are well above targets (fasting 4.4 to 7.2, postprandial below 10 mmol/L) and there are already microvascular complications.
• Retinopathy and macular edema: from the ophthalmologist's conclusion.
• Diabetic kidney disease: proteinuria, enlarged kidneys with thick cortex (typical early hyperfiltration pattern), reduced estimated glomerular filtration rate, coexisting retinopathy and hypertension.
• Suspected infection: leukocyturia of 20 to 22 per field, cloudy urine, weakly positive costovertebral angle tapping sign on both sides, and a dilated pelvicalyceal system.
• Hypertension: a muffled first sound and accent of the second sound over the aorta suggest left ventricular hypertrophy and a hypertensive heart. Shortness of breath needs echocardiography.

2. Interpretation of results

• Glycemic:
  • Glycated hemoglobin (essential and missing).
  • C-peptide and insulin.
  • GAD antibodies if the phenotype is atypical.
• Kidney:
  • Urine albumin-to-creatinine ratio, repeated twice within 3 to 6 months, and 24-hour protein.
  • Urine culture and Nechiporenko test.
  • Serum potassium, sodium, uric acid, and cystatin C if needed.
  • Bladder ultrasound with post-void residual volume.
  • Doppler of renal arteries.
• Lipid and liver:
  • Full lipid panel (LDL directly).
  • Alanine and aspartate aminotransferases, gamma-glutamyl transferase, alkaline phosphatase, bilirubin.
  • Liver ultrasound or fibrosis scoring for fatty liver.
• Pancreas:
  • Amylase and lipase.
  • Fecal elastase for exocrine insufficiency.
• Cardiovascular:
  • Electrocardiogram.
  • Echocardiography.
  • Natriuretic peptide if dyspnea persists.
  • 24-hour ambulatory blood pressure monitoring.
  • Carotid duplex and ankle-brachial index.
  • Stress testing if indicated.
• Neuropathy: 10 g monofilament, 128 Hz vibration, pinprick and ankle reflex testing, and orthostatic blood pressure for autonomic neuropathy.
• Other: thyroid-stimulating hormone, vitamin B12, and sleep apnea screening (obesity, night shifts, hypertension).
• Ophthalmology: optical coherence tomography and fluorescein angiography.

3. Management

Non-pharmacological

• Diet:
  • Medical nutrition therapy with a Mediterranean-type pattern and a deficit of 500 to 750 kcal/day.
  • Remove refined carbohydrates and fried food, and reduce saturated fat.
  • Salt below 5 g/day.
  • Protein about 0.8 g/kg/day for kidney disease.
  • Regular meal timing, which matters on night shifts.
  • Complete alcohol avoidance (pancreatitis, hypertriglyceridemia).
• Weight: loss of 5 to 10% or more.
• Activity: 150 minutes/week of moderate aerobic exercise plus resistance training 2 to 3 times/week. Avoid heavy straining and Valsalva-type effort until the macular edema is treated.
• Other lifestyle: stop smoking if applicable, sleep hygiene, and treat sleep apnea if present.
• Education: diabetes school, home glucose and blood pressure monitoring, foot care, hypoglycemia recognition, and sick-day rules.

Pharmacological

• Metformin (biguanide): titrate to 1000 mg twice daily with meals. This is safe at an estimated glomerular filtration rate above 45. Stop it during acute illness or contrast studies if renal function is unstable.
• Sodium-glucose cotransporter 2 inhibitor (empagliflozin 10 mg or dapagliflozin 10 mg daily):
  • Gives kidney, heart and weight benefit.
  • Start only after the urinary infection is treated and obstruction is excluded.
• Avoid:
  • Glucagon-like peptide 1 agonists and dipeptidyl peptidase 4 inhibitors, because of chronic pancreatitis. Semaglutide may also transiently worsen retinopathy if glucose falls too fast.
  • Pioglitazone, because it worsens fluid retention and macular edema.
• Step-up:
  • If the target is not reached in about 3 months, or in a catabolic state, add basal insulin (insulin glargine or degludec, starting at 0.1 to 0.2 units/kg).
  • Gliclazide modified-release is an alternative, but it carries hypoglycemia risk.
  • Lower glucose gradually, because rapid correction can transiently worsen retinopathy.

• Angiotensin-converting enzyme inhibitor (perindopril 5 to 10 mg, ramipril 5 to 10 mg) or angiotensin receptor blocker (losartan 50 to 100 mg, telmisartan 40 to 80 mg), titrated to the maximum tolerated dose. Never combine the two.
• Add amlodipine 5 to 10 mg or indapamide 1.5 mg early, because blood pressure is more than 20/10 mm Hg above target.
• Check creatinine and potassium 1 to 2 weeks after starting or changing the dose. A creatinine rise of up to 30% is acceptable.
• If albuminuria persists with potassium of 5.0 or below, add finerenone (nonsteroidal mineralocorticoid antagonist) 10 to 20 mg.

• High-intensity statin: atorvastatin 40 to 80 mg or rosuvastatin 20 mg (adjust for kidney function). Target LDL below 1.4 mmol/L and at least 50% reduction.
• Add ezetimibe 10 mg if the target is not reached.
• Fenofibrate can be considered for persistent hypertriglyceridemia and may slow retinopathy. Monitor creatinine.
• Antiplatelet therapy (aspirin 75 to 100 mg) for primary prevention is individualized according to bleeding risk.

• Ophthalmologist:
  • Intravitreal anti-vascular endothelial growth factor injections (aflibercept, ranibizumab, faricimab) for center-involving macular edema.
  • Focal or grid laser photocoagulation, or intravitreal corticosteroid implants, if needed.
  • Panretinal photocoagulation if the retinopathy becomes proliferative.
• Urinary infection:
  • Antibiotic chosen by urine culture and sensitivity (for example a cephalosporin or fluoroquinolone).
  • Urologic evaluation of the dilated collecting system.
• Neuropathy, if confirmed: alpha-lipoic acid, and pregabalin, gabapentin or duloxetine for pain.

• Basal or basal-bolus insulin if beta-cell failure or a pancreatogenic component is confirmed.
• Pancreatic enzyme replacement (pancrelipase) if exocrine insufficiency is present.
• Ursodeoxycholic acid or surgical review for chronic cholecystitis or gallstones.
• Review for bariatric surgery if the body mass index remains 30 or more with poor control.
• Vaccination: influenza, pneumococcal, hepatitis B and COVID-19.

Annual follow-up and monitoring

Core distinction

Why the distinction matters

• Both produce the same symptoms: palpitations, tremor, weight loss, heat intolerance, anxiety and low TSH with high free T4 or T3.
• Antithyroid drugs block synthesis, so they are ineffective in thyroiditis and expose the patient to side effects. Radioiodine is also useless when uptake is low.
• The cause is established by history, examination, antibodies, ESR or CRP, and a radioiodine uptake scan, which separates them best. Thyroid ultrasound with Doppler helps: Graves shows increased vascularity, while thyroiditis shows reduced flow.

Typical thyroiditis course (subacute, silent, postpartum)

1. Thyrotoxic phase (weeks 1 to 8): stored hormone leaks out.
2. Hypothyroid phase (months): the gland is depleted.
3. Recovery: usually back to normal, though some patients stay hypothyroid.

Note on terms